

Table 20.28

Cancer of the Oral Cavity and Pharynx (Invasive)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2009-2013
All Races, Both Sexes, by site

Histology ^a	Oral Cavity and Pharynx		Lip		Tongue		Salivary Gland		Floor of Mouth	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	43,177	84.8%	2,839	94.1%	14,862	97.4%	1,244	22.0%	2,440	95.7%
Squamous cell carcinoma (8070-8078,8083-8084)	42,191	82.8%	2,736	90.7%	14,614	95.8%	1,194	21.2%	2,417	94.8%
Adenocarcinoma ^c	5,046	9.9%	122	4.0%	213	1.4%	3,472	61.5%	78	3.1%
Other specific carcinomas ^d	466	0.9%	-	-	31	0.2%	269	4.8%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	1,612	3.2%	-	-	81	0.5%	439	7.8%	-	-
Sarcoma and soft tissue ^e	163	0.3%	-	-	21	0.1%	34	0.6%	-	-
Other specific types ^f	270	0.5%	24	0.8%	-	-	115	2.0%	-	-
Unspecified (8000-8005)	200	0.4%	-	-	39	0.3%	71	1.3%	-	-
Total	50,935	100.0%	3,017	100.0%	15,262	100.0%	5,644	100.0%	2,549	100.0%

Histology ^a	Gum and Other Mouth		Nasopharynx		Oropharynx and Tonsil		Hypopharynx		Other Oral Cavity and Pharynx	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Epidermoid carcinoma ^b (8051-8131)	5,497	81.8%	1,766	63.3%	10,954	97.8%	2,737	97.3%	838	89.1%
Squamous cell carcinoma (8070-8078,8083-8084)	5,247	78.0%	1,621	58.1%	10,818	96.6%	2,718	96.7%	826	87.8%
Adenocarcinoma ^c	988	14.7%	87	3.1%	57	0.5%	-	-	17	1.8%
Other specific carcinomas ^d	36	0.5%	42	1.5%	41	0.4%	17	0.6%	-	-
Unspecified, Carcinoma, NOS (8010-8011,8020-8022)	60	0.9%	832	29.8%	103	0.9%	31	1.1%	42	4.5%
Sarcoma and soft tissue ^e	31	0.5%	35	1.3%	-	-	-	-	-	-
Other specific types ^f	91	1.4%	-	-	-	-	-	-	-	-
Unspecified (8000-8005)	20	0.3%	17	0.6%	20	0.2%	-	-	21	2.2%
Total	6,724	100.0%	2,791	100.0%	11,195	100.0%	2,812	100.0%	941	100.0%

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Epidermoid carcinoma includes squamous, basal, and transitional cell carcinomas.

^c Adenocarcinoma includes histologies 8050, 8140-8147, 8160-8162, 8180-8221, 8250-8507, 8514, 8520-8551, 8560, 8570-8574, 8576, 8940-8941.

^d Other specific carcinomas includes histologies 8012-8015, 8030-8046, 8150-8155, 8170-8180, 8230-8249, 8508, 8510-8513, 8561-8562, 8575, 8580-8671.

^e Sarcoma and soft tissue includes histologies 8680-8713, 8800-8921, 8990-8991, 9040-9044, 9120-9136, 9150-9252, 9370-9373, 9540-9582.

^f Other specific types includes histologies 8720-8790, 8930-8936, 8950-8983, 9060-9110, 9260-9365, 9380-9539.

- Statistic not shown due to fewer than 16 cases during the time period.